Imunon, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $6.9M
- Price
- $1.64
- % Change (Daily % change from the live per-ticker quote feed.)
- +3.80%
- Volume
- 58.9K
About
Imunon, Inc. is a clinical-stage biotechnology company dedicated to the development and commercialization of DNA-based immunotherapies, vaccines, and directed chemotherapies. The company's pipeline features GEN-1, a DNA-based immunotherapy specifically designed for the localized treatment of ovarian cancer, and ThermoDox, a proprietary heat-activated liposomal formulation of doxorubicin, currently in development for various cancer indications. Additionally, Imunon possesses two feasibility-stage platform technologies aimed at creating nucleic acid-based immunotherapies, vaccines, and other anti-cancer DNA or RNA therapies. Established in 1982 and based in Lawrenceville, New Jersey, the firm was known as Celsion Corporation before rebranding to Imunon, Inc. in September 2022.
Quick stats
Shares outstanding4.2M
Computed float4.0M
Float / shares96.2%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000749647
Websitehttps://www.imunon.com
AI Summary
AI-generated1/16
majorbullishearnings
IMUNON Reports Second Quarter 2026 Financial Results and Provides Business Update
IMUNON reported final Phase 2 data for IMNN-001 showing a 45.1-month overall survival, a 14.7-month improvement over standard of care, marking a potential new standard for frontline ovarian cancer treatment.
Enrollment in the pivotal Phase 3 OVATION 3 study is exceeding forecasts and is now expected to complete in the first half of 2029.
Financially, the company posted a Q2 net loss of $2.8 million with $6.9 million in cash, bolstered by a $10 million financing transaction closed in June.
Red flags
- Low cash position of $6.9 million relative to $7.0 million cash used in operations over the last six months